Edwards Lifesciences Corporation revised earnings guidance for the full year 2024. For the year, the company now expects full-year 2024 sales growth to be at the high end of the prior guidance of 8% to 10% and $6.3 billion to $6.6 billion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
92.37 USD | -1.04% |
|
+1.62% | +21.14% |
06-20 | Edwards Lifesciences Insider Sold Shares Worth $492,258, According to a Recent SEC Filing | MT |
06-17 | Edwards Lifesciences Corporation Announces Executive Changes | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.14% | 55.66B | |
+4.18% | 211B | |
+8.00% | 185B | |
+31.86% | 158B | |
+2.74% | 64.32B | |
+0.11% | 48.41B | |
-6.76% | 37.82B | |
+0.78% | 35.57B | |
+11.28% | 28.12B | |
+14.97% | 23.58B |
- Stock Market
- Equities
- EW Stock
- News Edwards Lifesciences Corporation
- Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year 2024